Sunovion has acquired exclusive US marketing rights to three Novartis DPIs for the treatment of COPD, the company has announced. The company said that it plans to market the Utibron (indacaterol/glycopyrrolate) Neohaler, Seebri (glycopyrrolate) Neohaler, and Arcapta (indacaterol) Neohaler beginning in 2017.
Novartis will continue to manufacture the three products, which are known as Ultibro Breezhaler, Seebri Breezhaler, and Onbrez Breezhaler outside of the US.
Arcapta Neohaler was approved by the FDA in 2011 and launched in the US by Novartis in 2012. Utibron and Seebri Neohalers were approved by the FDA in 2015.
Sunovion Executive VP and Chief Commercial Officer David Frawley commented, “Sunovion has a long-standing commitment to advancing respiratory health and to providing new treatment options for people with COPD. We are pleased to add Utibron Neohaler, Seebri Neohaler and Arcapta Neohaler to our respiratory portfolio as these will complement our existing products and allow us to provide a wide range of treatment options for people with COPD.”
Novartis Pharmaceuticals Corporation President Fabrice Chouraqui said, “Given the evolving market dynamics, we believe these products will have the greatest impact in the US when commercialized by a company with an established presence in the COPD field. Novartis will continue to focus on areas in the US where we have strong capabilities and leadership, and can bring the greatest value to physicians and patients.”
Read the Sunovion press release.
Read the Novartis press release.
